[Informative value of immunomembrane indicator of glomerulonephritis activity and effectiveness of membranostabiliser dimephosphon].
OBJECTIVE
Study of effectiveness of dimephosphone with regard of the kind and degree of membrane disorders in various clinicomorphological forms of active glomerulonephritis (GN).


METHODS
170 patients with nephrotic, nephritic GN have undergone a complete nephrological examination. Informative value of immunological, morphological and membrane (phospholipids, lipid peroxidation) indicators of GN and lupus nephritis (LN) activity was analysed.


RESULTS
Membrane destabilisation and GN activity were correlated. Membrane destabilization was also associated with dislipid- and disproteinemia, disturbances of renal function. This can be used for diagnosis of GN activity and its rapid progression. Dimephosphone monotherapy was found effective in correction of immunomembrane disturbances in minimally active GN and hormone-resistant forms irrespectively of the activity forms. Combination of dimephosphone with prednisolone and/or cytostatics proved more effective than dimephsphone monotherapy or conventional treatment with glucocorticoids and/or cytostatics without dimephosphone in respect of frequency of remission and early remission achievement in various types of activity and clinicomorphological forms of GN.


CONCLUSIONS
Combination of dimephosphone with glucocorticoids and/or cytostatics is more effective than monotherapy or combined treatment with glucocorticoids and cytostatics in the treatment of GN of different clinicomorphological forms, hormone-resistant among them, and types of activity.
Sigitova
O N
ON
Maksudova
A N
AN
D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000936:Antigen-Antibody Complex / Q000097:blood / Q000652:urine; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood / Q000652:urine; D001706:Biopsy; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005260:Female; D005920:Glomerular Mesangium / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D005921:Glomerulonephritis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D015227:Lipid Peroxidation; D008297:Male; D008875:Middle Aged; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010743:Phospholipids / Q000097:blood / Q000276:immunology / Q000652:urine; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000936:Antigen-Antibody Complex; D000970:Antineoplastic Agents; D015415:Biomarkers; D005938:Glucocorticoids; D009943:Organophosphorus Compounds; D010743:Phospholipids; C049638:dimephosphon
Ob informativnosti immunomembrannykh pokazateleĭ aktivnosti glomerulonefrita i éffektivnosti membranostabilizatora dimefosfona.